Besins Healthcare, a global pharmaceutical company specialising in reproductive hormonal health, recently announced the acquisition of UniD Manufacturing, a Belgium-based pharmaceutical development and manufacturing company with more than 20 years of recognised expertise in long-acting drug delivery technologies.[1]
This acquisition brings together two highly compatible areas. Besins Healthcare brings deep expertise in reproductive hormone therapies for women’s and men’s health, such as oestrogen and progesterone for women, and testosterone for men. UniD contributes advanced capabilities in technologies that can enable more differentiated, less frequently administered treatment approaches.
UniD works with the advanced polymer technology used in the development and manufacture of complex long-acting delivery systems.[1]
Besins Healthcare will acquire the UniD site located in Seraing, Belgium, and 52 highly skilled professionals will transfer to the company. As part of this new chapter, UniD Manufacturing will be renamed Besins Healthcare PharmTech and will progressively become a center of excellence dedicated to innovation and future development projects. In the immediate term, UniD will continue to operate as usual and serve its current clients with the same professionalism and commitment.
“This acquisition unites two teams with deep and complementary expertise, and we couldn’t be more pleased to welcome UniD to Besins Healthcare,” said Nicolas and Alexandre Besins, Co-CEOs, Besins Healthcare. “This is a natural partnership for both companies, and we are excited about what lies ahead.”
“We are proud of what the UniD team has built over the past 20 years, and we are delighted to see those capabilities take on a new dimension as part of Besins Healthcare,” said Marc Foidart, Executive Chairman at UniD Manufacturing, who will step down from his role. “The UniD team looks forward to innovating further with Besins Healthcare, as well as continuing to serve our existing clients with the same commitment they have always received.”
Over the last 10 years, Besins Healthcare has experienced sustained, double-digit growth, with revenues reaching over €700 million in 2025, continuing a trajectory that has established the company as one of the fastest-growing companies in the hormonal health sector. [2]
References:
[1] We are UniD. Available at https://www.unid-manufacturing.com/. Last accessed July 2026
2 Data on file.
Source: Ogilvy Health
Image: UniD Manufacturing’s Headquarters in Seraing, Belgium, supplied by Ogilvy Health
